如何降低肺癌术后复发风险是学界探索多年的老大难问题。此前，CheckMate-816 以全球首个国际多中心 III 期临床肺癌新辅助免疫治疗研究的姿态荣登新英格兰医学杂志，成为可切除非小细胞肺癌的重要治疗手段之一。 2023 欧洲肿瘤内科学会（ESMO）上，来自美国 MD ...

Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) Compared to Opdivo Monotherapy in Patients with Microsatellite ...

Patients experienced a 38% reduction in the risk of disease progression or death when treated with Opdivo plus Yervoy versus Opdivo monotherapy across all lines of therapy at median 47 months of ...